drugset / Trial / NCT05176925
Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the 1-year progression free survival (PFS) rate of tislelizumab combined with sitravatinib as assessed by investigators per RECIST 1.1.
Timeline
- Start
- 2021-01-10
- Primary completion
- 2022-06-27
- Completion
- 2022-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sitravatinib | Small molecule | 100 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |